The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with Section 130a (8) SGB V for drugs containing the active ingredient epoetin zeta (recombinant human erythropoietin) as part of a so-called "open-house model". All interested and suitable pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V, subject to uniform conditions and a uniform access procedure. There is no exclusivity. The purchase quantity is unknown when the agreement is concluded and depends in particular on the demand from the insured, the development of the number of insured, the prescription behavior of contract doctors and the dispensing and stocking behavior of public pharmacies. The client does not guarantee any minimum purchase quantities.

For further information see point II.2.4) of the announcement.

The agreement can be concluded at any time and on the same terms. Individual contract negotiations are not carried out.

Interested pharmaceutical companies can request the participation documents (discount agreement, self-declaration that there are no grounds for exclusion, declaration of conformity) via the e-mail address mentioned under I.1). Agreements under this model are concluded between April 16, 2021 and May 31, 2023. Interested parties have the fully completed and signed participation documents (self-declaration that there are no grounds for exclusion, discount agreement in duplicate, declaration of conformity) for the first time by April 15, 2021, then by the 15th of a month, by post to the address mentioned under I.1) Submit position. It depends on the access of both AOK Plus. If the 15th of a month falls on a Saturday, Sunday or national public holiday, the next working day takes the place of such a day. In the event of a later receipt (after April 15, 2021 or the 15th of a month), the submitted participation documents will be taken into account on the 15th of the following month.

The discount agreement comes into effect on June 1st, 2021 if both parties sign it up to and including May 31, 2021. If the time of signing the AOK Plus is after May 31, 2021, this discount agreement comes into force as soon as the AOK Plus has signed the discount agreement after receipt of the complete documents signed by the pharmaceutical company. The signing takes place by the end of the month in which the participation documents must be received by AOK Plus. From an organizational point of view, AOK Plus must have a lead time of around half a month in order to report the discount agreement. The initial labeling of the discount drugs in the pharmacy software takes place from the second month following the deadline for receiving the participation documents. This point in time may vary in the event of changes or re-setting of the deadlines for the reporting on the national AOK contract reporting portal DatRabatt. A discount agreement is concluded with all pharmaceutical companies who meet the requirements for participation and who confirm this by signing the requested documents. The contract ends on May 31, 2023 at the latest, regardless of the date on which the contract was concluded. AOK Plus reserves the right to terminate the open-house procedure prematurely, especially in the case of the conclusion of exclusive discount agreements. In this case, the contracts already concluded will end in accordance with the contractual provisions. According to the experience of AOK Plus, exclusive discount agreements usually come into force 8 to 12 months after the publication of the corresponding announcement in the supplement to the Official Journal of the European Union. The future contractual partners in the open-house model are asked to regularly inform themselves in this regard in the supplement to the Official Journal of the European Union.